MX2023000316A - Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson. - Google Patents
Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson.Info
- Publication number
- MX2023000316A MX2023000316A MX2023000316A MX2023000316A MX2023000316A MX 2023000316 A MX2023000316 A MX 2023000316A MX 2023000316 A MX2023000316 A MX 2023000316A MX 2023000316 A MX2023000316 A MX 2023000316A MX 2023000316 A MX2023000316 A MX 2023000316A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- methods
- pharmaceutical compositions
- treating parkinson
- parkinson
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a composiciones farmacéuticas y métodos para el tratamiento y/o prevención y/o controlar la enfermedad de Párkinson y/o síntomas relacionados en un paciente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063066386P | 2020-08-17 | 2020-08-17 | |
US202163229021P | 2021-08-03 | 2021-08-03 | |
PCT/IB2021/057474 WO2022038475A1 (en) | 2020-08-17 | 2021-08-13 | Pharmaceutical compositions and methods for treating parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000316A true MX2023000316A (es) | 2023-02-22 |
Family
ID=80223734
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000316A MX2023000316A (es) | 2020-08-17 | 2021-08-13 | Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson. |
MX2023000314A MX2023000314A (es) | 2020-08-17 | 2021-08-13 | Formulaciones farmaceuticas transdermicas de cannabinoides. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000314A MX2023000314A (es) | 2020-08-17 | 2021-08-13 | Formulaciones farmaceuticas transdermicas de cannabinoides. |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220047541A1 (es) |
EP (2) | EP4196114A1 (es) |
JP (2) | JP2023537675A (es) |
CN (2) | CN115884760A (es) |
AU (2) | AU2021328741A1 (es) |
CA (2) | CA3187582A1 (es) |
MX (2) | MX2023000316A (es) |
WO (2) | WO2022038475A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2023011948A (es) * | 2021-04-12 | 2023-10-17 | Pike Therapeutics Inc | Entrega transdermica de cannabidiol:. |
US20230059204A1 (en) * | 2021-08-03 | 2023-02-23 | Pike Therapeutics, Inc. | Transdermal micro-dosing delivery of pharmaceutical agents |
GB202206000D0 (en) * | 2022-04-25 | 2022-06-08 | Univ Stellenbosch | Leonotis leonurus extracts as a chemoprotectant and post-chemotherapeutic agent |
US20240024253A1 (en) * | 2022-07-21 | 2024-01-25 | Pike Therapeutics Inc. | Continuous Drug Delivery Systems and Methods |
CN116077419B (zh) * | 2023-02-24 | 2023-10-27 | 丽珠集团新北江制药股份有限公司 | 一种犬用盐酸司来吉兰透皮吸收剂及其制备方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617356B2 (en) * | 2000-01-03 | 2003-09-09 | Naturally Scientific Inc | Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements |
US20020111377A1 (en) * | 2000-12-22 | 2002-08-15 | Albany College Of Pharmacy | Transdermal delivery of cannabinoids |
US8449908B2 (en) * | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
CA2657332A1 (en) * | 2006-07-14 | 2008-01-17 | Wine, Harvey | Transdermal formulations of synthetic cannabinoids and nano colloidal silica |
EP2424568A1 (en) * | 2009-04-29 | 2012-03-07 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
LT2473475T (lt) * | 2009-08-31 | 2017-08-10 | Zynerba Pharmaceuticals, Inc. | Kanabidiolio provaisto panaudojimas vietiniam arba transderminiam įvedimui su mikroadatomis |
WO2011027786A1 (ja) * | 2009-09-07 | 2011-03-10 | ニプロパッチ株式会社 | 経皮吸収型製剤 |
CA2805693A1 (en) * | 2010-07-20 | 2012-01-26 | Phytopharm Plc | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
US20160022627A2 (en) * | 2014-04-18 | 2016-01-28 | Mary's Medicinals LLC | Transdermal cannabinoid patch |
US9375417B2 (en) * | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
BR112017018944A2 (pt) * | 2015-03-02 | 2018-05-15 | Afgin Pharma Llc | método de tratamento de um estado ou condição de doença em humanos com um medicamento carbinóide, e, método de tratamento de um estado ou condição de doença em um mamífero diferente de um humano com medicamento(s) carbinóide(s) |
US10272125B2 (en) * | 2015-09-14 | 2019-04-30 | Life Tech Global, Llc | Transdermal delivery of cannabidiol with other active moieties including cannabinoids |
AU2017324262B2 (en) * | 2016-09-07 | 2023-06-22 | Glia, Llc | Treatment of symptoms related to neurodegenerative disorders through pharmacological dermal activation of cranial nerves |
WO2018071452A1 (en) * | 2016-10-11 | 2018-04-19 | Growblox Life Sciences L.L.C. | Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases |
CA3075719A1 (en) * | 2017-09-19 | 2019-03-28 | Zynerba Pharmaceuticals, Inc. | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults |
US11141172B2 (en) * | 2018-04-11 | 2021-10-12 | Globus Medical, Inc. | Method and apparatus for locking a drill guide in a polyaxial hole |
US20210361612A1 (en) * | 2018-10-15 | 2021-11-25 | Amnon Vardi | Slow release cannabinoids and products thereof |
US11660283B2 (en) * | 2018-12-19 | 2023-05-30 | Joyn Botanicals Ltd. | Cannabinoid-containing composition |
AU2019412825A1 (en) * | 2018-12-27 | 2021-08-12 | Buzzelet Development And Technologies Ltd. | Herbal preparation-enriched cannabinoid composition and method of treatment |
EP3906025A4 (en) * | 2019-01-04 | 2022-09-21 | Columbia Care LLC | CANNABINOID TOPICAL FORMULATIONS |
US10842758B1 (en) * | 2019-06-18 | 2020-11-24 | Ampersand Biopharmaceuticals, Inc. | Transdermal penetrant formulations containing cannabidiol |
US20220000794A1 (en) * | 2020-07-01 | 2022-01-06 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations for the treatment of multiple sclerosis |
-
2021
- 2021-08-13 MX MX2023000316A patent/MX2023000316A/es unknown
- 2021-08-13 CN CN202180050965.XA patent/CN115884760A/zh active Pending
- 2021-08-13 MX MX2023000314A patent/MX2023000314A/es unknown
- 2021-08-13 CN CN202180050966.4A patent/CN115884761A/zh active Pending
- 2021-08-13 WO PCT/IB2021/057474 patent/WO2022038475A1/en active Application Filing
- 2021-08-13 CA CA3187582A patent/CA3187582A1/en active Pending
- 2021-08-13 US US17/401,374 patent/US20220047541A1/en active Pending
- 2021-08-13 EP EP21857855.7A patent/EP4196114A1/en active Pending
- 2021-08-13 AU AU2021328741A patent/AU2021328741A1/en active Pending
- 2021-08-13 CA CA3187588A patent/CA3187588A1/en active Pending
- 2021-08-13 AU AU2021328742A patent/AU2021328742A1/en active Pending
- 2021-08-13 JP JP2023503426A patent/JP2023537675A/ja active Pending
- 2021-08-13 EP EP21857852.4A patent/EP4196113A4/en active Pending
- 2021-08-13 US US17/401,598 patent/US20220047525A1/en active Pending
- 2021-08-13 WO PCT/IB2021/057483 patent/WO2022038479A1/en active Application Filing
- 2021-08-13 JP JP2023501570A patent/JP2023537840A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115884760A (zh) | 2023-03-31 |
CN115884761A (zh) | 2023-03-31 |
AU2021328741A1 (en) | 2023-02-02 |
JP2023537675A (ja) | 2023-09-05 |
EP4196114A1 (en) | 2023-06-21 |
AU2021328742A1 (en) | 2023-02-02 |
EP4196113A4 (en) | 2024-04-03 |
WO2022038479A1 (en) | 2022-02-24 |
CA3187582A1 (en) | 2022-02-24 |
US20220047525A1 (en) | 2022-02-17 |
MX2023000314A (es) | 2023-02-22 |
US20220047541A1 (en) | 2022-02-17 |
CA3187588A1 (en) | 2022-02-24 |
EP4196113A1 (en) | 2023-06-21 |
WO2022038475A1 (en) | 2022-02-24 |
JP2023537840A (ja) | 2023-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000316A (es) | Composiciones farmaceuticas y metodos para el tratamiento de la enfermedad de parkinson. | |
NO20074980L (no) | Sammensetninger og fremgangsmater for topisk paforing og transdermal avlevering av botulinumtoksiker. | |
BRPI0409185A (pt) | formulações veterinárias anti-helmìnticas tópicas | |
NO20081593L (no) | Depotsammensetning | |
CR20210201A (es) | Nuevos compuestos antihelmínticos | |
BRPI0507895A (pt) | composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório | |
AR055591A1 (es) | Una composicion topica protectora de la piel y su uso | |
BR112022020769A2 (pt) | Compostos de 2,4-dioxopirimidina de inibição de cd73 | |
CA2451040A1 (en) | Gum resin for topical administration of pharmacologically active agents | |
ATE489082T1 (de) | Pharmazeutische zusammenstellungen zur behandlung von hautzuständen | |
WO2007056491A3 (en) | Film-forming resins as a carrier for topical application of pharmacologically active agents | |
WO2003086291A3 (en) | Urea compositions | |
US8636988B2 (en) | Composition for treatment of sunburned skin | |
BRPI0519605A2 (pt) | composiÇÕes de cuidado pessoal | |
AR069349A1 (es) | Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular | |
AR048587A1 (es) | Composiciones quimicamente estables de 4-hidroxitamoxifeno | |
JP2011513304A5 (es) | ||
BR112022020315A2 (pt) | Novos compostos anti-helmínticos | |
MX2023002613A (es) | Composiciones de matriquina derivada de tejidos y metodos para su realizacion. | |
WO2003032985A3 (en) | Concomitant oral and topical administration of anti - infective agents | |
HRP20090022T3 (en) | Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences | |
ATE548043T1 (de) | Polymorphe von 3-o-(3',3'- dimethylsuccinyl)betulinsäure-di-n-methyl-d- glucamin | |
WO2007132273A3 (en) | Rinse-off therapeutic agents for treating skin | |
AR089132A1 (es) | Composicion microbicida y su proceso de obtencion | |
SA520412443B1 (ar) | تركيبات للعين تُعطى مرة يوميًا من مركبات بنزيميدازول |